HC Wainwright Issues Positive Forecast for PLYX Earnings

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) – Equities research analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for Polaryx Therapeutics in a research report issued to clients and investors on Tuesday, November 10th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.04) per share for the quarter, up from their prior estimate of ($0.06). The consensus estimate for Polaryx Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Polaryx Therapeutics’ Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.18) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.24) EPS.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings upgraded shares of Polaryx Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, November 2nd. Raymond James Financial started coverage on shares of Polaryx Therapeutics in a report on Thursday, August 13th. They set a “strong-buy” rating and a $6.00 target price for the company. Finally, Wall Street Zen raised Polaryx Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $7.67.

Polaryx Therapeutics Trading Up 4.3%

NASDAQ:PLYX opened at $1.95 on Thursday. The company has a fifty day moving average of $1.97 and a 200 day moving average of $3.09. Polaryx Therapeutics has a 52 week low of $1.69 and a 52 week high of $48.91.

Polaryx Therapeutics (NASDAQ:PLYX) last issued its earnings results on Thursday, August 13th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.02.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.